OBJECTIVE: CYP2C9 is a major enzyme in human drug metabolism and the polymorphism
observed in the corresponding gene may affect therapeutic outcome during treatment. The …

Phenytoin (PHT) is an antiepileptic drug widely used in the treatment of focal epilepsy and
status epilepticus, and effective in controlling focal seizures with and without tonic–clonic …

Background: Genetic polymorphisms of CYP2C9 can lead to wide inter-individual variations
in drug metabolism. Decreased metabolism leads to higher plasma levels, causing adverse …

Methods: A total of 402 patients with epilepsy were enrolled in this study; 128 were drug
resistant and 274 were drug responsive. The peripheral blood samples of the patients with …

Cytochrome (CYP) P450 enzymes are responsible for metabolism of antiepileptic drugs
(AEDs), and encoded by highly polymorphic genes. A case–control study was conducted in …

Abstract Objective Cytochrome P450 2C9 and 2C19 (CYP2C9 and CYP2C19, respectively)
genetic polymorphisms play an important role in phenytoin (PHT) metabolism. We have …

Objective Epilepsy is a neurologically based disease. Literature data indicate a certain
association between the polymorphism of these genes, which participate in the metabolism …

Abstract Background and Objective Despite the availability of several antiepileptic drugs,
drug resistance remains one of the major challenges in epilepsy therapy. Genetic factors are …

Epilepsy is a major global issue. Epilepsy patients are treated with AED (antiepileptic drugs).
Interindividual variability in drug response has been documented in several studies. The …

Phenytoin has a widespread use in epilepsy treatment and is mainly metabolized by hepatic
cytochrome P450 enzymes (CYP). We have investigated CYP2C9* 2, CYP2C9* 3 …